1globe Health Institute LLC

BEIJING, China,--( BUSINESS WIRE )--Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, announced today its unaudited financial results for the six months ended June 30, 2022. First Half of 2022 Financial Summary Sales for the six-month period ended June 30, 2022 were $1.2 billion, compared to $11.0 billion in the prior year period. Net income attributable to common shareholders totaled $481.6 million, or $4.84 per basic and $4.24 per diluted share, in the six-month period ended June 30, 2022, compared to net income attributable to common shareholders of $5.1 billion, or $51.42 per basic and $44.80 per diluted share, in the prior year period. Mr. Weidong Yin, Chairman, President and CEO of SINOVAC, commented, “The COVID-19 pandemic will ultimately end, but the past three years have again demonstrated the importance of vaccination to fight against infectious diseases and the global need to build a resilient health system. SINOVAC is the largest Chinese COVID-19 vaccine provider and is also working to provide accessible pharmaceutical products to meet increasing worldwide healthcare demand. In parallel, Sinovac’s regular non-COVID-19 vaccine business grew 37% year over year. In addition, two products passed WHO prequalification providing further proof of Sinovac’s overall vaccine production quality system and creating new commercial opportunities outside of China. Also in 2022, we invested heavily into R&D on COVID-19 vaccines in different age groups and technological platforms. While we have proved that our inactivated vaccine is safe and effective on children, our recombinant vaccine candidate is ready for IND.” Business Updates COVID-19 Vaccine – CoronaVac ® , the inactivated COVID-19 vaccine developed by SINOVAC, has been approved for use in more than 60 countries and regions worldwide. At this time, over 2.9 billion doses of CoronaVac ® have been delivered globally, making SINOVAC the largest China-based COVID-19 vaccine provider the international market. Notably, CoronaVac ® has become the only inactivated COVID-19 vaccine in the world approved for use for children as young as six months old, after the Secretary of Health of the HKSAR of the PRC approved the lowering of the minimum age for receiving CoronaVac ® from three years to six months old for "off-label use" in early August 2022. By gaining worldwide recognition and approvals, the Company and its scientific research partners are continuously carrying out a number of real-world studies and clinical trials in different countries and regions. According to a phase III clinical trial of CoronaVac ® among children aged 6 to 35 months, a high level of antibody positive conversion was observed with the antibody level equal to, or higher than that of adults. In 2022, study results have also confirmed the safety and effectiveness of CoronaVac ® for pediatric and adolescent populations in Chile, as well as the adequate prevention from three doses of SINOVAC COVID-19 vaccine, especially for individuals over 60 years old, from several Omicron waves in Hong Kong. Sabin Inactivated Polio Vaccine (“sIPV”) – the Poliomyelitis Vaccine (Vero Cell), inactivated, Sabin strains, was prequalified by the World Health Organization (“WHO”) in June 2022, and sIPV is now available for United Nations (UN) agencies to purchase to support the global polio endgame strategy. Hepatitis A Vaccine – Healive ® , the first and only WHO prequalified hepatitis A vaccine from China, celebrated its 20 th anniversary of market launch in July 2022. With more nations’ healthcare authorities’ approvals, such as Kenya and Indonesia this year, Healive ® has been registered in 21 countries and organizations around the world and authorized to be administered in 33 countries and regions, to susceptible individuals over 12 months old. Varicella Vaccine – the live attenuated varicella vaccine was prequalified by WHO in November 2022, marking the first WHO prequalified Chinese varicella vaccine, and the fourth SINOVAC vaccine to receive WHO approval. Quadrivalent Influenza Vaccine (“QIV”) – the latest development of SINOVAC's influenza vaccine product family, entered the global market this year, by gaining a couple of overseas commercialization approvals. A phase III clinical trial for QIV was initiated in Chile through a collaboration with the Pontificia Universidad Católica de Chile in July. Unaudited Financial Results for the First Half of 2022 Sales for the first half of 2022 were $1.2 billion, compared to $11.0 billion in the prior year period. The decrease was due to the lower sales of CoronaVac ® as the initial two-dosage vaccination schedules were completed around the globe in 2021 and third booster shots were only administered in certain countries including China in 2022. Sales of non-pandemic vaccines increased 37% from $128 million to $ 176 million on broad-based growth, especially in seasonal influenza vaccine. Selling, general and administrative expenses in the first half of 2022 were $155.9 million, compared to $162.7 million in the prior year period. Selling, general and administrative expenses did not decrease in proportion to total sales as expenses incurred to sell CoronaVac ® in the comparative period were a relatively low proportion of CoronaVac ® revenues. R&D expenses in the first half of 2022 were $184.4 million, compared to $53.9 million in the prior year period. The increase was due to the largely invested into R&D on COVID-19 vaccines and overseas clinical trials of regular products. Net income in the first half of 2022 was $790.4 million, compared to $8.6 billion in the prior year period. Net income attributable to common shareholders was $481.6 million, or $4.84 per basic and $4.24 per diluted share, in the first half of 2022, compared to a net income attributable to common shareholders of $5.1 billion, or $51.42 per basic and $44.80 per diluted share, in the prior year period. As the Company announced on February 22, 2019, the Company’s Board of Directors determined that certain shareholders became acquiring persons, as defined in the Company’s rights agreement (“Rights Agreement”), under which a trigger event occurred. As a result, the Company issued new common and preferred shares of SINOVAC. Without the effect of implementing the Rights Agreement and newly-issued common and preferred shares, basic and diluted earnings per share for the first half of 2022 would be $6.76 and $5.61, respectively. Non-GAAP adjusted EBITDA was $691.3 million in the first half of 2022, compared to $10.2 billion in the prior year period. Non-GAAP net income was $628.8 million in the first half of 2022, compared to $8.6 billion in the prior year period. Non-GAAP diluted earnings per share in the first half of 2022 was $3.41 compared to $44.78 per share in the prior year period. Non-GAAP diluted earnings per share in the first half of 2022, excluding the implementation of the Rights Agreement and the newly-issued common and preferred shares, would be $4.51. Reconciliations of non-GAAP measures to the nearest comparable GAAP measures are included at the end of this earnings announcement. As of June 30, 2022, cash and cash equivalents and restricted cash totaled $6.9 billion, compared to $11.6 billion as of December 31, 2021. In the first half of 2022, net cash used in operating activities was $808.2 million, net cash used in investing activities was $3.6 billion and net cash provided by financing activities was $11.7 million. The Company’s first half of 2022 financial statements are prepared and presented in accordance with U.S. GAAP. However, they have not been audited or reviewed by the Company’s independent registered accounting firm. Legal Proceedings Antigua Litigation As previously disclosed by the Company, on March 13, 2018, 1Globe Capital LLC (“1Globe”) filed a complaint against the Company in the Antigua Court. The trial of the matter took place from December 3 to 5, 2018. On December 19, 2018, the Antigua judge handed down his judgment (the “Antigua Judgment”), finding fully in favor of the Company, dismissing 1Globe’s claim and declaring the Rights Agreement was validly adopted as a matter of Antigua law. On January 29, 2019, 1Globe filed a Notice of Appeal against the Antigua Judgment. On March 4, 2019, 1Globe filed an application for urgent interim relief, seeking an injunction to prevent the Company from continuing to implement its Rights Agreement until the resolution of the appeal. This application was heard on April 4, 2019, at which the Court of Appeal issued an order restraining the Company from operating the Rights Agreement in any way that affects 1Globe’s rights or shareholding or otherwise distributing the exchange shares to the Company’s shareholders who did not trigger the Rights Plan until after the determination of the appeal (the “Exchange Shares”). 1Globe’s appeal against the Antigua Judgment was heard on September 18, 2019, and the appeal decision was announced by the Eastern Caribbean Supreme Court, Court of Appeal (the “Court of Appeal”) on December 9, 2021, upholding the Antigua Judgment in each point. The Court of Appeal also confirmed that SINOVAC’s Rights Agreement was consistent with its Articles of Incorporation and By-laws, and Antiguan business law. In January 2022, the Court of Appeal extended the order initially made on April 4, 2019, that restrains SINOVAC from taking further action under its Rights Agreement, including the distribution of the previously issued Exchange Shares, until the conclusion of any appeal to the Privy Council. 1Globe applied for leave to appeal to the Judicial Committee of the Privy Council (the “Privy Council”), and the hearing of the application was held on February 24, 2022, in which the Court of Appeal granted 1Globe leave to appeal to the Privy Council on certain grounds, although not including the challenge to the validity of the Rights Agreement. On April 19, 2022, 1Globe renewed its application directly to the Privy Council for leave to appeal on its ground of appeal concerning the validity of the Rights Agreement. On July 13, 2022, 1Globe filed its Notice of Appeal on those grounds on which the Court of Appeal had granted 1Globe leave to appeal. On September 16, 2022, 1Globe filed an application to the Privy Council seeking permission to amend its existing application for permission to appeal, and its existing Notice of Appeal, and to seek permission to appeal on another ground rejected by the Court of Appeal concerning the exercise of the Antigua Court’s discretion. Sinovac responded on October 21, 2022, and the parties now await a decision from the Privy Council upon these procedural applications. 1Globe has not yet taken steps to list a substantive hearing before the Privy Council. US Litigation As previously disclosed, on March 5, 2018, the Company filed a lawsuit in the Court of Chancery of the State of Delaware, seeking a determination on whether 1Globe, the Chiang Li Family, OrbiMed Advisors, LLC and certain other shareholders of the Company had triggered the Rights Agreement. On April 12, 2018, 1Globe filed an amended answer to the Company’s complaint, counterclaims and a third-party complaint against the Company and Mr. Weidong Yin, alleging, among other allegations, that the Rights Agreement is not valid. On March 6, 2019, the Delaware Chancery Court entered a status quo order, providing that the Company not distribute any of the Exchange Shares to the Company’s shareholders who did not trigger the Rights Plan until the final disposition of the pending Delaware litigation or further order of the Court. On April 8, 2019, the Delaware Chancery Court stated that the Delaware litigation was pending the final outcome of 1Globe’s appeal of the Antigua Judgment. Separately, Heng Ren Investments LP (“Heng Ren”) filed suit against SINOVAC and Weidong Yin on May 31, 2019 in Massachusetts state court for the alleged breach of fiduciary duties and wrongful equity dilution. SINOVAC moved the matter from the state court to Massachusetts federal court. Heng Ren alleged that Mr. Yin breached fiduciary duties owed to minority shareholders, that SINOVAC aided and abetted breaches of fiduciary duties and that both SINOVAC and Mr. Yin engaged in wrongful equity dilution in connection with the private placement of SINOVAC common shares (the “PIPE”) with private investors in 2018. Heng Ren requested damages, attorney fees, and prejudgment interest. In July 2021, SINOVAC moved to dismiss Heng Ren’s amended complaint. On March 4, 2022, the court granted the motion as to the breach of fiduciary duty claims, denied the motion as to the wrongful equity dilution claim, and denied reconsideration of its decision on the motion. SINOVAC had answered the complaint, and the litigation is pending. On December 5, 2022, a purported shareholder filed a putative class action complaint in Massachusetts federal court, asserting a claim under Section 204 of the Antigua and Barbuda International Business Corporations Act related to the PIPE transaction, alleging that all shareholders were harmed in an identical manner to one another by the PIPE transaction because the shares that were issued in the PIPE transaction allegedly undervalued the Company and all shareholders were purportedly wrongfully diluted as a result. The purported shareholder is represented by the same attorney who represents Heng Ren, and requests damages, attorneys’ fees, and prejudgment interest. The matter is in preliminary stages. PRC Litigation On May 16, 2018, Sinovac Hong Kong filed a complaint against Sinobioway Medicine, Mr. Aihua Pan, and Shandong Sinobioway Biomedicine Co., Ltd. in the Beijing Fourth Court. The complaint sought to hold the defendants jointly and severally liable for the torts they committed during an attempt of the defendants to take physical control of our facility in Shangdi site in Beijing on April 17, 2018. Later, Sinovac Hong Kong made an application to the court to add Sinovac Beijing as a third party to participate in the proceedings. The court has granted an order, permitting Sinovac Beijing to participate in the proceedings as a third party. At the hearing held on July 2, 2019, Sinovac Hong Kong, the defendants and Sinovac Beijing cross-examined the evidences submitted by each party. Based on the result of the cross-examination, the court declared that an independent evaluation firm shall be engaged by both the defendants and Sinovac Hong Kong to evaluate the losses and damages sustained by Sinovac Beijing as the result of the actions taken by the defendants on April 17, 2019. An independent evaluation firm was selected by the court and the evaluation was conducted accordingly. On September 17, 2020, the Beijing Fourth Court issued a judgment holding Sinobioway Medicine and Mr. Aihua Pan liable for torts and breaches of shareholders fiduciary duty under the PRC Company Law and liable for Sinovac Beijing’s losses of RMB15.4 million caused by their disruptive actions. Sinovac Beijing, Sinobioway Medicine and Mr. Aihua Pan filed notice to appeal to the Higher People’s Court of Beijing Municipality. On October 31, 2022, the Higher People’s Court of Beijing Municipality issued a judgment in favor of Sinovac Hong Kong, upholding the judgment issued by the Beijing Fourth Court and ruling that Shandong Sinobioway Biomedicine, as the sole shareholder of Sinobioway Medicine, is jointly and severally liable for all the relevant obligations of Sinobioway Medicine to Sinovac Hong Kong. On November 15, 2021, Sinobioway Medicine filed a complaint against Sinovac Beijing and Sinovac Hong Kong in Beijing Fourth Court. The complaint sought to dissolve and liquidate Sinovac Beijing with the argument that the board of directors of Sinovac Beijing has been unable to function for the benefit of the company and the two shareholders of Sinovac Beijing have gotten into a deadlock. The case is pending. In November 2021, Sinobioway Medicine filed a complaint against Sinovac LS, Sinovac Hong Kong, Mr. Weidong Yin and Keding Investment (Hong Kong) Limited with the Beijing Fourth Court, claiming that Sinovac LS has infringed the legitimate rights of Sinovac Beijing when doing the research and development of CoronaVac. Sinobioway Medicine listed Sinovac Beijing as a third party in the case. The case is pending. Status of Exchange Shares and Trading in the Company’s Shares As a result of the pending legal proceedings described above, the Exchange Shares are expected to remain in a trust for the benefit of the Company’s shareholders who did not trigger the Rights Plan until, at least, the conclusion of the appeal against the Antigua Judgement and the final disposition of the Delaware litigation or further order of the Delaware Chancery Court. The Exchange Shares remain issued and outstanding. The Nasdaq Stock Market LLC implemented a halt on trading of the Company’s common shares at the time the Exchange Shares were issued to the trust. The Company is currently unable to estimate when trading will resume, or if Nasdaq will take any additional action in regards to trading of the Company’s common shares. The Holding Foreign Companies Accountable Act Our auditor, Grant Thornton Zhitong Certified Public Accountants LLP, is an independent registered public accounting firm. In December 2020, the US Congress enacted the Holding Foreign Companies Accountable Act (“HFCAA”), which directs the US Securities and Exchange Commission (the “SEC”) to delist from US stock exchanges any company if the company’s principal audit firm is in a country in which the US Public Company Accounting Oversight Board (“PCAOB”) is unable to conduct a complete inspection of the firm. In December 2021, the PCAOB published a report providing its view that authorities in China and Hong Kong prevented the PCAOB from inspecting audit firms headquartered in China and Hong Kong. The list of audit firms included our auditor. However, on December 15, 2022, the PCAOB announced that it was effectively reversing its determination that it is unable to inspect audit firms based in Mainland China and Hong Kong. The PCAOB’s action follows an August 2022 agreement among the PCAOB, the China Securities Regulatory Commission (“CSRC”) and the Ministry of Finance of the PRC (“MOF”) that provided a framework for PCAOB inspections and several weeks of on-the-ground work by PCAOB staff in Hong Kong to conduct those inspections. In December 2022, congressional action shortened the HFCAA timeline for a potential trading prohibition from three years to two years. Despite the reversal from the PCAOB, the SEC indicated that the PCAOB’s inspection work of audit firms in China must continue in order to avoid having companies again face a potential delisting under the HFCAA, and China-based companies that list in the United States are expected to provide specific and prominent disclosures about heightened operational and legal risks associated with their business. About SINOVAC Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases. SINOVAC’s product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected hand-foot-mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, mumps, etc. The COVID-19 vaccine, CoronaVac ® , has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive ® , passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive ® , is an innovative vaccine under "Category 1 Preventative Biological Products" and commercialized in China in 2016. In 2022, SINOVAC’s Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO. SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1 ® , which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu ® , to the Chinese government stockpiling program. SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations. For more information, please visit the Company’s website at www.sinovac.com . Safe Harbor Statement This press release may include certain statements that are not descriptions of historical facts, but are forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates” and similar statements. Forward-looking statements involve risks, uncertainties and other factors that could cause actual results to differ materially from those contained in any such statements. In particular, the outcome of any litigation is uncertain, and the Company cannot predict the potential results of the litigation it filed or filed against it by others. Additionally, the triggering of a shareholder rights plan is nearly unprecedented, and the Company cannot predict the impact on the Company or its stock price as a result of the trigger of the rights plan. Non-GAAP Financial Measures To supplement its consolidated financial statements, which are prepared and presented in accordance with GAAP, SINOVAC uses the following non-GAAP financial measures: non-GAAP adjusted EBITDA, non-GAAP net income and non-GAAP diluted EPS. For more information on these non-GAAP financial measures, please refer to the table captioned “Reconciliations of non-GAAP Measures to the Nearest Comparable GAAP Measures” in this results announcement. SINOVAC believes that non-GAAP adjusted EBITDA, non-GAAP net income and non-GAAP diluted EPS help identify underlying trends in its business that could otherwise be distorted by the effect of certain income or expenses that SINOVAC includes in net income and diluted EPS. SINOVAC believes that non-GAAP adjusted EBITDA, non-GAAP net income and non-GAAP diluted EPS provide useful information about its core operating results, enhance the overall understanding of its past performance and future prospects and allow for greater visibility with respect to key metrics used by our management in its financial and operational decision-making. Non-GAAP adjusted EBITDA, non-GAAP net income and non-GAAP diluted EPS should not be considered in isolation or construed as an alternative to income from operations, net income, diluted EPS, or any other measure of performance or as an indicator of SINOVAC’s operating performance. These non-GAAP financial measures presented here may not be comparable to similarly titled measures presented by other companies. Other companies may calculate similarly titled measures differently, limiting their usefulness as comparative measures to our data. Non-GAAP adjusted EBITDA represents net income and excludes interest and financing expenses, interest income, net other income and income tax benefit (expenses), and certain non-cash expenses, consisting of share-based compensation expenses, amortization and depreciation that SINOVAC does not believe are reflective of the core operating performance during the periods presented. Non-GAAP net income represents net income before share-based compensation expenses and foreign exchange gain or loss. Non-GAAP diluted EPS represents non-GAAP net income attributable to common shareholders divided by the weighted average number of shares outstanding during the periods on a diluted basis, including accounting for the effect of the assumed conversion of options. SINOVAC BIOTECH LTD. Consolidated Balance Sheets As of June 30, 2022 and December 31, 2021 (Expressed in thousands of U.S. Dollars) June 30, 2022 December 31, 2021 (Unaudited) Current assets Cash and cash equivalents $ 6,857,905 $ 11,608,855 Restricted cash 9,189 10,905 Short-term investments 4,988,240 1,806,449 Accounts receivable - net 969,561 952,402 Inventories 266,864 375,511 Prepaid expenses and deposits 23,328 160,987 Total current assets 13,115,087 14,915,109 Property, plant and equipment – net 949,422 903,298 Prepaid land lease payments 44,932 39,730 Intangible assets - net 1,315 1,480 Long-term prepaid expenses 24 25 Long-term investments 697,115 655,835 Prepayments for acquisition of equipment 129,721 65,290 Deferred tax assets 64,821 52,031 Right-of-use assets 63,347 115,376 Total assets 15,065,784 16,748,174 Current liabilities Short-term bank loans and current portion of long-term bank loans 104 3,099 Loan from a non-controlling shareholder 1,501 1,582 Accounts payable and accrued liabilities 334,294 1,020,651 Income tax payable 158,540 1,267,504 Deferred revenue 32,763 79,941 Deferred government grants 11,209 12,559 Dividend payable 20,083 17,125 Lease liability 6,367 10,385 Total current liabilities 564,861 2,412,846 Deferred government grants 7,265 4,870 Long-term bank loans 12,150 12,668 Deferred tax liability 325,917 324,164 Loan from a non-controlling shareholder 4,479 4,708 Lease liability 57,118 112,465 Other non-current liabilities 137 444 Total long-term liabilities 407,066 459,319 Total liabilities 971,927 2,872,165 Commitments and contingencies Equity Preferred stock 15 15 Common stock 100 100 Additional paid-in capital 547,691 547,691 Subscriptions receivable - (7,109 ) Accumulated other comprehensive income (loss) (217,469 ) 130,622 Statutory surplus reserves 1,514,297 1,514,297 Accumulated earnings 7,623,373 7,141,819 Total shareholders' equity 9,468,007 9,327,435 Non-controlling interests 4,625,850 4,548,574 Total equity 14,093,857 13,876,009 Total liabilities and equity $ 15,065,784 $ 16,748,174 SINOVAC BIOTECH LTD. Consolidated Statements of Comprehensive Income For the six months ended 2022 and 2021 (Expressed in thousands of U.S. Dollars, except for numbers of shares and per share data) Six months ended June 30 2022 2021 (Unaudited) (Unaudited) Sales $ 1,212,290 $ 10,981,056 Cost of sales 254,362 631,766 Gross profit 957,928 10,349,290 Selling, general and administrative expenses 155,880 162,657 Provision (recovery) for doubtful accounts 807 (561 ) Research and development expenses 184,394 53,911 Loss on disposal of property, plant and equipment 3,286 294 Government grants recognized in income (14 ) (686 ) Total operating expenses 344,353 215,615 Operating income 613,575 10,133,675 Interest and financing expenses (623 ) (1,522 ) Interest income 83,998 30,804 Other income (expense), net 229,458 (949 ) Income before income taxes 926,408 10,162,008 Income tax expense (135,962 ) (1,569,934 ) Net income 790,446 8,592,074 Less: income attributable to non-controlling interests (305,934 ) (3,483,748 ) Net income attributable to shareholders of Sinovac 484,512 5,108,326 Preferred stock dividends (2,958 ) (2,958 ) Net income attributable to common shareholders of Sinovac 481,554 5,105,368 Net income 790,446 8,592,074 Other comprehensive income, net of tax of nil Foreign currency translation adjustments (579,251 ) 30,995 Comprehensive income 211,195 8,623,069 Less: comprehensive income attributable to non-controlling interests (74,774 ) (3,495,019 ) Comprehensive income attributable to shareholders of Sinovac 136,421 5,128,050 Earnings per share Basic net income per share 4.84 51.42 Diluted net income per share 4.24 44.80 Weighted average number of shares of common stock outstanding Basic 99,502,243 99,294,743 Diluted 114,172,782 114,013,068 SINOVAC BIOTECH LTD. Consolidated Statements of Cash Flows For the six months ended 2022 and 2021 (Expressed in thousands of U.S. Dollars) Six months ended June 30 2022 2021 (Unaudited) (Unaudited) Operating activities Net income $ 790,446 $ 8,592,074 Adjustments to reconcile net income to net cash provided by operating activities: Deferred income taxes (15,837 ) (70,894 ) Share-based compensation - 1,512 Inventory provision 56,203 1,433 Provision (recovery) for doubtful accounts 807 (561 ) Loss on disposal of property, plant and equipment 3,286 294 Depreciation of property, plant and equipment 75,159 16,526 Amortization of prepaid land lease payments 2,503 1,372 Amortization of intangible assets 97 89 Government grants recognized in income (14 ) (686 ) Changes in: Accounts receivable (140,015 ) (1,133,990 ) Inventories 37,251 (301,530 ) Income tax payable (1,083,624 ) 1,327,797 Prepaid expenses and deposits 133,914 (42,465 ) Deferred revenue (45,121 ) (32,856 ) Accounts payable and accrued liabilities (622,923 ) 729,031 Other non-current liabilities (298 ) (9 ) Net cash provided by (used in) operating activities (808,166 ) 9,087,137 Financing activities Proceeds from bank loans 199 13,346 Repayments of bank loans (3,038 ) (13,902 ) Proceeds from shares subscribed - 37 Dividend paid to non-controlling shareholders (2,469 ) (37,798 ) Proceeds from subsidiary's financing 12,000 - Government grants received 5,021 1,235 Loan from a non-controlling shareholder - 7,110 Repayments of loan from a non-controlling shareholder (12 ) (25 ) Net cash provided by (used in) financing activities 11,701 (29,997 ) Investing activities Purchase of short-term investments (15,123,334 ) (4,379,773 ) Proceeds from redemption of short-term investments 11,890,425 1,548,716 Proceeds from disposal of equipment 603 52 Prepaid land lease payments (9,658 ) (12,390 ) Acquisition of property, plant and equipment (279,398 ) (431,485 ) Purchase of long-term investments (63,280 ) - Net cash used in investing activities (3,584,642 ) (3,274,880 ) Effect of exchange rate changes on cash and cash equivalents and restricted cash (371,559 ) 23,896 Increase (decrease) in cash and cash equivalents and restricted cash (4,752,666 ) 5,806,156 Cash and cash equivalents and restricted cash, beginning of period 11,619,760 1,050,204 Cash and cash equivalents and restricted cash, end of period 6,867,094 6,856,360 SINOVAC BIOTECH LTD. Reconciliations of Non-GAAP measures to the nearest comparable GAAP measures For the six months ended 2022 and 2021 (Expressed in thousands of U.S. Dollars, except for numbers of shares and per share data) Six months ended June 30 2022 2021 (Unaudited) (Unaudited) Net income $ 790,446 $ 8,592,074 Adjustments: Share-based compensation - 1,512 Depreciation and amortization 77,759 17,987 Interest and financing expenses, net of interest income (83,375 ) (29,282 ) Other expense (income), net (229,458 ) 949 Income tax expense 135,962 1,569,934 Non-GAAP adjusted EBITDA 691,334 10,153,174 Net income 790,446 8,592,074 Less: Foreign exchange gain (161,619 ) (5,153 ) Add: Share-based compensation - 1,512 Non-GAAP net income 628,827 8,588,433 Net income attributable to common shareholders of Sinovac 481,554 5,105,368 Add: Preferred stock dividends 2,958 2,958 Net income attributable to common shareholders of Sinovac for computing diluted earnings per share 484,512 5,108,326 Add: Non-GAAP adjustments to net income (95,093 ) (1,830 ) Non-GAAP net income attributable to common shareholders of Sinovac for computing non-GAAP diluted earnings per share 389,419 5,106,496 Weighted average number of shares on a diluted basis 114,172,782 114,013,068 Diluted earnings per share 4.24 44.80 Add: Non-GAAP adjustments to net income per share (0.83 ) (0.02 ) Non-GAAP diluted earnings per share 3.41 44.78

又到一年年末，大家放松心情整理行囊之前都有一件不得不做的事，就是做这一年的年终总结。对于很多上市药企而言，2022年并不好过，更不好过的是，很多失败，还不能甩锅给疫情。对上市公司而言，沪深两大交易所的问询函是监管风向标。交易所普遍会针对财务报告、并购重组、关联交易、股票异常波动和媒体报道的社会热点等事件发出问询函，要求上市公司在规定时间内书面回函并公开披露。而今年有些上市公司“触发”问询函的原因，总是让人哭笑不得。现金不翼而飞、子公司失控、管理层大打出手……2022年，这些上市药企们踩过的坑，2023年还会再踩一遍吗？曾豪言收购“修正药业”，如今股价“腰斩”，前董事长被捕近日，吉药控股公告称，经吉林证监局调查，吉药控股涉嫌信息披露违法，吉药控股及其子公司因融资租赁、担保、金融借款、民间借贷等事项，发生重大诉讼6起，连续十二个月累计涉诉金额为8.04亿元，拟对公司、原董事长孙军以及原总经理许蔚合计罚款390万元。这并不是吉药控股第一次涉嫌信披违规，2019年7月，因为吉药控股先发公告称拟收购体量远大于自己的东北传统药企修正药业，短短几日后又宣布终止收购，股价大起大落的同时，也因信披违规受到了证监会处罚。因受疫情影响，吉药控股自2022年5月5日开市起停牌。直至6月29日才发布了2021年年报，随后，公司股票于6月30日开市起复牌同时被实施退市风险警示及其他风险警示，股票简称由“吉药控股”变更为“*ST吉药”。在年报中吉药控股提到，由于公司流动资金严重短缺，公司及部分子公司2021年度多项金融机构借款和融资租赁借款逾期、欠息，引发多起诉讼、导致多个银行账户被冻结、多项资产被查封，公司及部分子公司生产经营受到严重影响，致使公司本年度归属于上市公司股东净利润继续亏损。而其会计师事务所对财务报告的审计意见为：无法表示意见。经营一团糟的同时，公司原高管也不让人省心。8月12日晚，ST吉药公告称收到公安机关通知，公司原董事长孙军，原董事、副总经理王德恒因涉嫌职务犯罪已被批准逮捕。2018年至2021年，*ST吉药分别实现净利润2.17亿元、-17.72亿元、-3.8亿元和-4.51亿元。“子公司失控”，“并购大户”瑞康医药下一步还“买买买”吗？12月15日晚间，瑞康医药公告称，拟收购关联方持有的山东乐康金岳实业有限公司（以下简称乐康金岳）9.6409%的股份；交易完成后，乐康金岳将成为上市公司的全资子公司。在2022年陷入“子公司失控”的处境中后，最后并购大户的瑞康生物并没有就此停下步伐。早在2021年，瑞康医药公告称部分被收购子公司与公司发展战略发生分歧，拟有序清退，就开始起诉子公司追借款。诉讼案件总金额达11.74亿元，其中涉及瑞康医药子公司的诉讼金额高达9.54亿元。随后，瑞康生物2021年年报显示，因对未来期间经营管理未能达成一致，自2021年1月1日始，对甘肃瑞康医药有限公司及其子公司、太原维康鸿业科技有限公司及其子公司、北京金凯惠医疗器械有限责任公司及其子公司失去控制；自2021年10月1日始，对郑州源生吉医疗科技有限公司及其子公司失去控制。深交所随后在年中问询函中要求瑞康医药就“子公司失控”等问题进行解释，并要求公司于2022年5月23日前书面回复该函件。自2015年以来，瑞康医药不断扩张，几年时间内已经并购了一百多家公司。但规模扩大对营收的影响却未必全是好事。自2015年以来，瑞康医药营收从97.5亿一路攀升至2019年的352.59亿，随后大幅回落，净利润同样在连续上涨后呈现下滑趋势，2019年净亏损为9.28亿元，2020年和2021年才堪堪“回暖”。子公司“被”非法入股，未名医药报警立案11月23日，未名医药发布公告称，针对杭州强新生物科技有限公司入股公司控股子公司未名生物医药有限公司事项，公司已于2022年8月12日向淄博市公安局张店分局报案，淄博市公安局张店分局认为符合立案条件，立案侦查。据悉，今年8月，深交所曾向未名医药下发关注函，收到投资者投诉，杭州强新以约29亿元入资厦门未名，获得厦门未名约34%的股份，该事项已于2022年5月18日完成工商变更，根据协议，杭州强新将向厦门未名委派一名董事。但未名医药在10月份给深交所的回复函中表示，公司时任董事及时任董秘在2022年5月18日后陆续知晓杭州强新入股厦门未名。公司董事会确定未收到过杭州强新入股厦门未名事宜的相关文件，未就杭州强新入股厦门未名事宜召开过董事会，未就杭州强新入股厦门未名事宜履行过相应的审议程序，也不存在厦门未名敦促本公司履行信息披露义务信息的情形。目前公安机关已介入调查，相关工作仍在进展中。值得注意的是，未名医药还在回复中表示，公司对厦门未名拥有控制权，不存在失去控制权的情形。董事长曾“失联”，公司退市，揽海医疗梦碎上海滩2022年11月，据中国执行信息公开网显示，览海控股再次被列入被执行人名录，执行标的约为780万元，公司目前被执行总金额已达到11.23亿元。这家自诞生起就“高举高打”，又有名人效应背书的机构如今已然从繁华处退场，只留下令人唏嘘的故事结局。2016年，览海控股进行产业转型，进军医疗领域。因其实控人密春雷妻子董卿央视主持人的身份，这起跨界转型“范本”一直以来颇受关注。揽海医疗旗下一度6家子公司，其中有专科医院、综合医院、康复中心等等。不过，医疗的壁垒之高，远非资本可以轻易撬动。2022年年初，密春雷去向不明，6月20日，览海医疗发布公告称，上交所决定终止公司股票上市，涉及超3万股民投资者。与此同时还有其未按规定披露关联方资金占用、关联方债权未收回等信息，海南证监局因此对揽海医疗及密春雷等人采取出具警示函的行政监管措施，2022年7月25日，揽海医疗被上海证券交易所予以摘牌。华北制药36.75亿现金“不翼而飞”被质疑6月20日，华北制药收到了上交所的信息披露监管工作函，要求其对2021年年报的财务信息进行说明。其中华北制药在冀中能源集团财务有限责任公司存款余额在四个月间“不翼而飞”被质疑。据悉，根据华北制药年报及相关公告披露，截至2021年12月31日，华北制药在冀中能源集团财务有限责任公司存款余额为44.2亿元，2022年1月1日，公司使用财务公司存款偿还河北银行贷款本金及利息，财务公司存款余额降至36.75亿元；截至报告披露日，也就是4月27日，公司在财务公司的存款余额为0元。上交所要求华北制药说明这36.75亿元的去向，以及报告披露日至今是否新增存入财务公司存款。今年7月，华北制药回复了上交所的问题称，财务公司存款取出后未实施专户存储管理。财务公司存款及利息36.9亿元取出后转入物资供应分公司农业发展银行账户，主要用于日常生产经营活动、偿还银行借款支出等。自2021年年度报告披露日至今无新增存入财务公司存款。基石药业理财亏5000万元今年6月1日，停牌了两个月的基石药业-B终于恢复了交易，但值得注意的是，在恢复交易的头一天，即5月31日，基石药业还在公告中称由于投资理财亏损超5000万元。事情的经过是，2021年6月，时任基石药业财务副总裁的翁晓路发现投资事项机会并与相关第三方磋商，其后向时任首席执行官建议使用公司闲置资金投资招银国际及招银国际金融的银行集团，并声称投资事项能产生低风险的良好回报。得到首席执行官的口头批准后，翁晓路安排以CStone Pharm (HK)的名义于招银国际证券开设证券交易账户，并于2021年7月7日向招银国际证券汇款3000万美元。于2021年7月14日，翁晓路与招银国际证券确认认购本金额为约2.33亿港元，到期日为2021年12月30日。投资事项的总认购金额约为2.28亿港元（经扣除认购费用及其他开支后）。但这笔投资并非低风险，公告显示，截至2022年3月31日，未变现亏损约为名义金额的29%，也就是造成了大约超过5000万元的投资亏损。董事长引咎辞职，实控人取保候审，明星企业深陷资金“旋涡”作为首批登陆北交所的81家企业之一，也是首个遭北交所记录处分的药企，生物谷身上一度贴着大大的“惨”字。2022年4月底以来，因大股东占用生物谷超2亿资金，且迟迟无法归还，这家药企不仅屡遭监管问询，更是在不到一年的时间里经历了公司董事长、董秘等高管接连离职、公司第二大股东易主、实控人被取保候审、旗下在建项目延期等一系列变故。这些变故横生，起源于其年报的发布。2022年4月底，永中和会计师事务所对生物谷2021年年报出具了保留意见的审计报告，报告中提到，截至审计报告日，公司控股股东金沙江投资尚未归还生物谷资金合计2.77亿元。随后，北交所下发问询函，云南证监局同样对其出具了行政监管措施决定书。在受到监管机构关注后，生物谷大股东金沙江投资一度承诺将在6月30日前归还全部占用资金，但直到7月6日，仅归还了2000万元，仍有2.57亿元占用资金未收回。面对上市公司被大股东当“提款机”这一尴尬局面，生物谷原二股东海国新动能选择了“分手”，要求终止合作并退出金沙江投资，并与林艳和签署协议约定，约定林艳和以2.28亿元受让海国新动能持有的金沙江投资27.52%股权。原股东选择抽身离开的同时，公司高管们也开始选择离开是非之地。生物谷董事长林艳和、董事会秘书杨智玲和监事会主席蔡泽秋也于7月23日递交辞职报告。其中，林艳和的辞职原因是“个人原因”，杨智玲和蔡泽秋的辞职原因皆为“工作原因”。入职生物谷前后不到1个月的原总经理助理徐天水被选为公司新任董事长。9月底，生物谷公告表示实控人林艳和已被昆明市公安局取保候审，生物谷向深圳市中级人民法院申请财产保全，请求依法对其控股股东金沙江投资、实际控制人林艳和名下等值于2.73亿元的财产进行保全，即对金沙江和林艳和持有的全部生物谷股权进行了司法冻结或轮候冻结。原本风光无限的明星企业，徒留一地鸡毛。云南白药炒股赔近20亿元今年3月，云南白药披露了2021年业绩，全年营收363.74亿元，同比增长11.09%，归母净利润28.04亿元，同比增长-49.17%。值得注意的是，归母净利润出现下滑的主要原因是证券投资亏损。从年报披露数据来看，云南白药报告期内公允价值变动收益为-19.29亿元，形成变动的原因为“公司持有的证券、基金单位净值变化产生。”值得注意的是，在云南白药2022年中报中又披露了报告期内公允价值变动收益为-4.17亿元，形成原因依旧为“公司持有的证券、基金单位净值变化产生。”截至2022年上半年，尽管中报中说明本年处置了部分股票投资及基金投资，但云南白药的交易性金融资产仍高达28.88亿元。多年无实控人，嘉应制药夺权之争2021年9月，嘉应董秘被“关门殴打”一事冲上热搜，一时间，上市公司夺权上演“全武行”成为行业热议。事实上，这起事件的背后是嘉应制药内部两大派系老虎汇和新南方投资的“内斗风云”。据悉，嘉应制药长期处在无实控人的状态，此前其第一大股东老虎汇持股比例仅为持股比例为11.27%。而在引入朱拉伊的新南方投资后，老虎汇与新南方投资在2021年6月签订《表决权委托协议》，拟通过定增引入新南方投资，老虎汇将所持股份不可撤销地委托了给了新南方投资，达成了短暂的平衡。但之后由于新南方投资提名上述被殴打董秘黄利兵担任公司执行总经理遭到否决，以及新南方投资未能妥善处理所受让三位股东的利益，老虎汇、新南方投资双方“合作”破裂。去年11月，在嘉应制药第五次临时股东大会上，老虎汇一方的非独立董事徐胜利、独董肖义南被罢免，董事长朱拉伊取得董事会多数席位。今年9月，朱拉伊又因个人原因提交书面辞呈，辞去总经理一职，但仍担任公司董事长。迄今，嘉应制药总经理一职仍空缺。

五年和全球大流行在重塑行业方面会有什么不同。当激烈的制药公司在2017年最后公布我们的顶级疫苗参与者排名时，我们强调了全球五大公司。现在，部分感谢生物制药行业对这一流行病的反应，我们能够将名单的长度加倍，并包括几个新的参与者。这次，排名完全混乱。早在2017年，默克，葛兰素史克和赛诺菲等疫苗疣就位居榜首。现在，正如行业观察者和其他人所知道的那样，辉瑞正在占据疫苗世界的首位。在辉瑞公司主导地位的整个过程中，该公司一直与BioNTech合作进行mRNA研究和全球制造业扩张。他们在COVID shot Comirnaty方面的成功使德国mRNA专家能够弹射到2号位置。第三位是中国疫苗制造商科兴生物，去年销售额超过190亿美元。1辉瑞2021疫苗收入：426.3亿美元2022年上半年疫苗收入：254亿美元疫苗负责人：Nanette Cocero博士在创纪录的一年之后，辉瑞攀升至疫苗行业顶端也就不足为奇了。在2020年12月获得FDA紧急使用授权后，该公司的BioNTech合作伙伴COVID-19 shot推出全球知名度并扩大了生物制药销售图表。总体而言，辉瑞去年的shot销售额接近370亿美元。这些销售以全球政府的供应订单的形式出现。与其合作伙伴一起，辉瑞去年生产了30亿剂COVID-19疫苗，并表示预计到2022年将生产40亿剂。在大流行之前，辉瑞公司的疫苗业务集中在Prevnar 13，之前是世界上最畅销的疫苗，直到COVID-19发挥作用。2019年，即COVID-19之前的最后一年，该镜头产生了58.5亿美元，约占辉瑞总疫苗运输量的89%。如今，Prevnar特许经营仍在发挥很大作用，但其2021年的收入为527万美元，并未为Comirnaty蜡烛。辉瑞公司的其他疫苗也没有，例如脑膜炎B注射Trumenba，去年在全球范围内产生了1.18亿美元。现在，即使大流行已经消退，新型冠状病毒肺炎疫苗市场即将转向商业领域，辉瑞预计收入将继续增加。拜登政府表示，从明年开始，它不会继续购买这些照片和治疗方法，这要归功于辉瑞公司的商业技能“更适合”开放市场，首席执行官Albert Bourla博士在7月份的投资者电话中说。尽管大流行放缓，但仍在继续。7月，FDA批准该疫苗用于至少6个月大的学龄前儿童。该公司已经在6至17岁的儿童中使用了监管NOD，并且直到7月，该组中唯一可用的COVID-19疫苗。然后，在8月份，FDA将辉瑞公司和Moderna公司更新的omicron目标助推器点亮。2BioNTech2021疫苗收入：224.8亿美元2022年上半年疫苗收入：103亿美元商业领袖：UğurÁahin，首席执行官在未来几年里，行业观察者可能会保持目光，看看谁在信使RNA疫苗竞赛中领先。在几乎同时获得COVID-19 mRNA射击授权后，Moderna和辉瑞公司的德国合作伙伴BioNTech不仅建立了这项技术，而且还建立了几乎可以肯定是蓬勃发展的行业的公司。到目前为止，与辉瑞公司在COVID jab，Comirnaty上分拆利润的BioNTech在收入方面的表现略好于其跨大西洋竞争对手。到2021年，作为BioNTech唯一商业产品的Comirnaty帮助该公司下调了190亿欧元的销售额。展望未来，BioNTech今年预计将在130亿至170亿欧元附近产生收入。多位分析师和健康专家警告说，大流行头几年的销售沙拉日不会永远存在。鉴于世界大部分地区“决定与病毒生活在一起”，ODDO BHF分析师最近将BioNTech 2022年和2023年COVID-19疫苗销售的销售预测分别下调了28%和33%。到2022年，研究人员预计德国mRNA wunderkind将支付约140亿欧元，他们指出这是BioNTech指导的低端。虽然ODDO团队最初预计来自中国的“底部需求”每年约为1亿剂，以抵消Comirnaty的销售量，但该公司此后表示这些可能性为零。3科兴2021疫苗收入：193.7亿美元2022年上半年疫苗收入：未披露业务负责人：尹伟东，主席兼首席执行官中国的Sinovac Biotech在2021年的销售额几乎翻了两番，使Moderna在收入方面排名世界前三位的疫苗制造商之列。该公司的COVID-19疫苗CoronaVac是激增的主要驱动力。CoronaVac采用传统的灭活疫苗技术设计。虽然CoronaVac已获得世界卫生组织紧急使用清单的批准，但它被广泛认为不如Moderna和辉瑞生物科技公司的基于mRNA的疫苗有效。尽管如此，该疫苗在中国和一些中低收入国家的广泛采用使Sinovac的2021年销售额达到了1937亿美元，而2020年为5.11亿美元，2019年为2.46亿美元。该疫苗于2020年8月获得特殊中国人参与医疗保健专业人员等高风险人群的接种，并于2021年2月在有条件的上市许可下扩大向公众使用。截至2021年12月下旬，该公司在全球范围内提供了超过25亿剂CoronaVac，公司的年度申报显示。2021年7月，Sinovac与疫苗联盟Gavi签署了一份预先购买协议，提供高达3.8亿剂CoronaVac，以便在2022年上半年之前根据COVAX疫苗权益计划分发。但由于自2019年2月以来的交易下跌，纳斯达克上市公司的投资者未能从巨大的收入收益中获得全部收益。由于投资公司1Globe Capital领导的一群活动家投资者企图政变，纳斯达克股票代码于2019年暂停了Sinovac的交易。股东激进主义的背景是在很快流产，混乱的私人过程中出现了令人讨厌的权力抓住。美国证券交易委员会（SEC）后来指控1Globe未能披露其在Sinovac中增加的股份，同时与其他人合作取代几乎整个Sinovac董事会。2020年，1Globe及其所有者以290000美元的民事处罚总额解决了案件，后来呼吁所有股东放弃分歧并共同努力支持CoronaVac。4Moderna2021疫苗收入：176.7亿美元2022年上半年疫苗收入：108.2亿美元业务负责人：Stéphane Bancel，首席执行官Moderna并不是来自世界第二大多产COVID-19疫苗的蓝色。早在2020年底马萨诸塞州的公司获得FDA对Spikevax的授权之前，这是一家热门的生物技术公司，为其吸引的资金设定了记录。2013年，阿斯利康与Moderna合作，以2.4亿美元的价格获得了有史以来从未在人类身上测试过药物的生物技术公司。然后在2015年和2016年，私人投资轮次分别达到4.5亿美元和4.75亿美元。在承诺其mRNA技术可以治愈癌症等目标之后，Moderna于2014年缩减规模，将重点转移到似乎不那么雄心勃勃的企业：疫苗。虽然这一举措让一些投资者感到失望，但事实证明这只是市场成功所需的现代票。当2020年大流行袭击时，美国转向的一家公司是Moderna。两年多后，政府向Moderna支付了近100亿美元用于研发，制造规模扩大和提前购买镜头。Moderna于2021年承诺现金，实现了176.7亿美元的疫苗销售，占公司总收入1847亿美元的大部分。今年，Spikevax在上半年超过了这个速度，销售额达到了105亿美元。公司根据提前订单预测它将在2022年下半年与该数字相匹配。今年早些时候，随着疫苗供应量的增加，Moderna同意推迟到2022年晚些时候到2023年运送到欧洲。5默沙东2021疫苗收入：96.9亿美元2022年上半年疫苗收入：49.7亿美元业务负责人：Robert Davis，首席执行官大流行带来了警觉性的改变，新型冠状病毒肺炎疫苗生产商取代了葛兰素史克，赛诺菲和默克等长期存在的疫苗疣。虽然在大流行爆发时默克公司预计会有很多事情发生，但公司进入竞争后期，从未接近开发新型冠状病毒疫苗，在辉瑞和Moderna获得FDA批准各自拍摄后不久就实施了两项计划。默克不是继续作为世界顶级疫苗卖方的统治地位，而是基于2021年的收入排在第五位，销售额为96.9亿美元。然而，如果COVID疫苗销售被排除在前10名之外，默克将无法占据疫苗收入报告的首位。而且，到2022年上半年，默克公司将获得49.7亿美元，将超过2021年的数字。默克公司的Gardasil继续占据HPV领域的主导地位，去年销售额为57亿美元，这与2020年大流行病的表现相比大幅反弹，当时销售额为39亿美元。Gardasil在2022年上半年继续蓬勃发展，销售额为31亿美元。在2018年和2019年需求超过供应之后，Gardasil的上半年增长也得益于制造业10亿美元的投资。现在，该公司认为Gardasil到2030年的销售额可能会翻一番，因为更多的制造资源计划在线。默克公司的另一家重磅炸弹疫苗特许经营权，其中包括用于预防麻疹，腮腺炎，风疹和水痘的ProQuad，以及仅防御水痘的Varivax，去年合计21亿美元。当销售额达到19亿美元时，这是大流行放缓的适度反弹。RotaTeq是一种预防幼儿轮状病毒的疫苗，继续稳步攀升，到2021年达到8.07亿美元。自2015年以来，shot每年都有收入增长。默克去年还出售了1.79亿美元的甲型肝炎疫苗Vaqta，高于1.7亿美元2020年。6葛兰素史克2021疫苗收入：93.2亿美元2022年上半年疫苗收入：42.2亿美元疫苗负责人：Roger Connor，疫苗负责人有一次，全球最大的疫苗接种者，如果其与赛诺菲的COVID-19合作伙伴关系扩大，葛兰素史克可能已经准备好继续保持这一排名。相反，这些公司陷入研发挫折，无法推出他们的COVID射击。不过，这并不是说葛兰素史克没有成功的疫苗组。去年全年，葛兰素史克的“皇冠珠宝”特许经营权有时被称为收入68亿英镑。如果使用2021年的平均英镑对美元汇率1.37转换为美元，那大约是93亿美元。而且，尽管葛兰素史克与赛诺菲的COVID-19合作尚未实现，但该公司与Medicago的合作确实取得了胜利。今年早些时候，Medicago的基于植物的COVID-19疫苗Covifenz在加拿大获得了监管部门的认可。该镜头包含了葛兰素史克的佐剂，据说这些合作伙伴正在关注其他地方的更多监管意见。总而言之，葛兰素史克2021年的疫苗销售业绩足以在全球排名中排名第六，仅次于四家COVID-19疫苗制造商和默克公司，后者的传统疫苗特许经营权胜过了我们2017年报告中的其他几家公司。葛兰素史克的疫苗业务包括重磅炸弹脑膜炎特许经营权，去年该特许经营权达到9.61亿英镑（13.1亿美元）。该公司去年的流感业务总额为6.79亿英镑，而其“成熟疫苗”集团的销售额高达29.7亿英镑。在其“既定”类别中，葛兰素史克销售针对肝炎的疫苗以及婴儿疫苗和助推器。7赛诺菲2021疫苗收入：74.5亿美元2022年上半年疫苗收入：23.2亿美元疫苗负责人：Thomas Triomphe，疫苗负责人与其欧洲制药同行葛兰素史克一样，赛诺菲长期以来一直拥有全球领先的疫苗特许经营权之一。但是当2020年大流行爆发时，这些公司无法履行共同使命，迅速提供有效的疫苗。尽管没有大流行，但赛诺菲的免疫业务仍然是全球药物制造商的主要收入来源。如果赛诺菲和葛兰素史克成功完成了他们的COVID-19 shot quest，他们可能已经达到或接近今年收入排名的顶端。在流感中，赛诺菲仍然是世界领先的疫苗参与者；该公司最近表示，预计2022年将有“创纪录”的一年。去年，赛诺菲的flu特许经营带来了26.3亿欧元，比2020年增长了6%。根据去年1.18欧元对美元的平均汇率，收入总额约为31亿美元。在其他地方，赛诺菲针对脊髓灰质炎，百日咳和B型流感嗜血杆菌的婴儿疫苗组最近一直在增长。特许经营在2021年减少了21.6亿欧元，比2020年增加了4%。赛诺菲还销售脑膜炎疫苗，去年产生6.58亿欧元，加上加强疫苗和旅行疫苗，分别减少4.88亿欧元和3.06亿欧元。该公司的所有疫苗特许经营均于2021年实现销售增长，推动集团范围内的收入增长63.2亿欧元（74.5亿美元）。但正是该公司与葛兰素史克的合作关系在2020年和2021年引起了如此多的头条新闻。2020年4月，这些公司在竞争对手的药品制造商之间建立了不寻常的合作关系，将葛兰素史克的大流行加强技术与赛诺菲的重组DNA疫苗平台相结合。8智飞生物2021疫苗收入：47.5亿美元2022年上半年疫苗收入：25.6亿美元业务负责人：姜仁生，主席兼总裁重庆智飞生物制品也许是默克公司重磅炸弹HPV疫苗Gardasil和Gardasil 9的中国合作伙伴。自2017年和2018年两次拍摄中国点头以来，需求一直耗尽供应，定期报告全国各地等待名单和难以获得疫苗。HPV疫苗已成为智飞业务的基石。在Gardasil于2018年与默克达成协议之前，智飞的收入一直徘徊在7亿元左右。2020年，该公司总运输量为152亿元。2021年，中国当局发布了880万剂Gardasil，全年增长22%。根据志飞的年度报告（中文），Gardasil 9的发布数量翻了一番，达到1020万剂。上升趋势一直持续到2022年。根据智飞半年报告，Gardasil释放量跃升60%至近490万剂量，Gardasil 9在2022年前六个月几乎翻了两番，达到约930万剂量。在8月份中国当局将Gardasil 9的合格人口扩大到9至45岁的女性之后，Gardasil特许经营将有望获得另一项收入增长。以前，只有16至26岁的女性才有资格获得九价射击。除了HPV注射外，志飞还是默克公司在新泽西制药的轮状病毒疫苗RotaTeq，肺炎球菌多糖疫苗Pneumovax 23和甲型肝炎疫苗Vaqta上的合作伙伴，所有这些疫苗在2021年和2020年都有增加的产品释放。总而言之，到2021年，默克合作的镜头为智飞的销售额增加了50%至209亿元。在2022年上半年，这些镜头以134%的年增长率拖入167亿元。9阿斯利康2021疫苗收入：39.8亿美元2022年上半年疫苗收入：16亿美元业务负责人：Pascal Soriot，首席执行官虽然阿斯利康设法实现了其COVID-19拍摄Vaxzevria的clinch重磅炸弹销售，但英国制药公司在疫苗聚光灯下的时间可能即将结束。该公司首席执行官Pascal Soriot今年早些时候告诉路透社，现在正在寻找心血管疾病和癌症等既定治疗领域的中小企业收购，阿斯利康正在考虑完全切断其疫苗业务。虽然阿斯利康的COVID-19疫苗是首批吸引全球监管机构的疫苗之一，但基于更传统疫苗技术的Vaxzevria却在Moderna和辉瑞生物科技的mRNA巨人的阴影下行走。更重要的是，AZ的Vaxzevria在生产方面挣扎，在欧洲延迟交货以及对稀有血栓的安全隐患。在疫苗推出初期，供应短缺引发了AZ高管和欧洲官员之间的来回交流。此后不久，人们担心疫苗对老年人的疗效。更为复杂的是，去年春天，欧洲国家的游行开始停止使用射击，担心血块的恐惧。在美国，阿斯利康的射击从未通过监管机构的穆斯特，美国的大部分疫苗传奇都围绕着一个拥有承包商紧急生物解决方案的主要制造钝化机。在交叉污染snafu讨论了看似不断扩大的AZ剂量之后，该公司被迫寻找新的生产合作伙伴。反过来，AZ承诺给美国的剂量已经成为该国疫苗捐赠的一部分，其中包括从紧急巴尔的摩工厂清除的某些剂量。根据纽约时报跟踪器的数据，Vaxzevria在美国和欧洲某些地区继续发挥重要作用，在这些地区，疫苗正在大约185个国家使用。截至去年11月，阿斯利康在新闻稿中表示，它已向“每个大陆170多个国家”发布了20亿剂COVID射击的供应自那时以来，该公司已在180多个国家发布了总计30亿剂药物，阿斯利康公司的一位发言人通过电子邮件告诉激烈的制药公司。她补充说，阿斯利康三分之二的Vaxzevria货物已运往中低收入国家。尽管如此，由于其颠簸的COVID推出仍然是AZ的新想法，该公司现在选择优先考虑其针对COVID-19和其他病毒（如呼吸道合胞病毒Soriot）的保护性抗体名单。10强生2021疫苗收入：23.9亿美元2022年上半年疫苗收入：10亿美元疫苗负责人：詹森全球疫苗负责人Penny Heaton尽管强生公司是激烈制药年度大型制药排名的首位狗，但该公司的疫苗组合并没有与其一些同行相媲美。制药巨头的主要疫苗，其COVID-19免疫接种，在整个运行过程中一直存在问题。这一射击在2021年获得了该公司23.9亿美元的销售额，这是一笔可观的金额，但对于去年在所有业务中下跌937.7亿美元的公司而言，这一数字几乎没有移动。J＆J于2021年2月下旬获得FDA批准用于其单剂量COVID-19疫苗，加入市场上辉瑞和Moderna的mRNA注射。在其3期试验中，shot在中重度疾病中有66%的疗效，在严重疾病中有85%的疗效。竞争对手Moderna和辉瑞提供了更高的功效，但J＆J能够一次性提供保护而不是二次。当时，许多人认为J＆J的剂量优势将推动疫苗接种。但在推出后不久，美国当局因担心稀有血栓而停止接种疫苗。J＆J的射击从未真正从那里恢复过来，制造合作伙伴紧急生物解决方案的问题当然没有帮助。到2022年4月，疫苗首次获得批准一年多后，该公司表示不再将其COVID-19疫苗纳入其收入预测。这个决定是在一个令人失望的销售季度之后做出的，当时该镜头的收入仅为4.57亿美元。早在1月份，J＆J就预测2022年的销售额在30亿美元到35亿美元之间。该公司的首席财务官约瑟夫·沃尔克（Joseph Wolk）认为，由于“全球供应盈余和疫苗在发展中市场的犹豫”，所有新型冠状病毒肺炎疫苗的需求都有所下降然后，以全面的方式，FDA可能会限制使用疫苗给那些无法获得其他疫苗的18岁及以上的人。原文来源；The top 10 vaccine companies worldwide (fiercepharma.com)